JOURNAL REVIEWED: Ophthalmology
Latest Contribution
Progression in the Early Manifest Glaucoma Trial
The Early Manifest Glaucoma Trial (EMGT) had previously demonstrated without doubt that intraocular pressure reduction decreased the risk of progression in patients with early glaucoma. In this analysis of 306 eyes over eight years from the EMGT, perimetric and optic...
Screening for hydroxychloroquine retinopathy
The American Academy of Ophthalmology has updated the recommendations for screening for hydroxychloroquine retinopathy based on new scientific evidence that toxicity is not rare when hydroxychloroquine is used long-term, and that risk is dependent on the daily dose by weight....
Aflibercept, bevacizumab or ranibizumab for DMO
This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...
